Achaogen is a biopharmaceutical company engaged in discovering, developing, and commercializing antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The company develops plazomicin for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The company also develops antibacterial candidate, C-Scape, an orally-administered combination of ceftibuten and clavulanate for oral treatment for patients with cUTI, and acute pyelonephritis, caused by expanded spectrum beta-lactamases-producing Enterobacteriaceae.

Famous Dave's of America develops, owns, operates and franchises restaurants under the name Famous Dave's. The company's prototypical design includes a designated bar, an exterior smokestack, a separate entrance for its To Go business and a patio. Each restaurant features a selection of hickory-smoked and off-the-grill barbecue products, side items, and handmade desserts. To complement its entree and appetizer items, the company provides six regional barbeque sauces: Rich & Sassy?, Texas Pit?, Georgia Mustard?, Devil's Spit?, Sweet and Zesty? and Wilbur's Revenge?.

Cerecor is a biopharmaceutical company. The company is building a pipeline of therapies in neurology, pediatric healthcare, and orphan rare diseases. The company's neurology pipeline is led by CERC-301, which is in a Phase I safety study for Neurogenic Orthostatic Hypotension. The company is also developing two other neurological clinical and preclinical stage compounds. The company's pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. All three of these compounds are preclinical therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation by means of substrate replacement therapy.

Destination Maternity is a designer and retailer of maternity apparel. The company operates in various retail locations, including stores in the U.S., Canada and Puerto Rico, and leased departments located within department stores and baby specialty stores throughout the U.S. and in Puerto Rico. The company also sells its merchandise on the Internet, primarily through its Motherhood.com, APeaInThePod.com and DestinationMaternity.com websites. In addition, the company has international store and product supply relationships in the Middle East, South Korea, Mexico and Israel. The company has various international franchised locations, comprised of stand-alone stores and shop-in-shop locations.

Harvest Capital Credit is an externally managed, closed-end, non-diversified management investment company. The company's investment objective is to generate both income and capital appreciation primarily by making direct investments in the form of subordinated debt, senior debt, and to a lesser extent, minority equity investments in privately-held United States small to mid-sized companies.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

Radius Health is a biopharmaceutical company focused on developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's commercial product, TYMLOSTM (abaloparatide) injection is designed for the treatment of postmenopausal women with osteoporosis at high risk for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The company is developing an abaloparatide transdermal patch for potential use in the treatment of postmenopausal women with osteoporosis. The company is also developing its Elacestrant, a selective estrogen receptor degrader, for potential use in the treatment of hormone receptor-positive breast cancer.